EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders

Cristina Nanni, Christophe M Deroose, Sona Balogova, Constantin Lapa, Nadia Withofs, Manil Subesinghe, Bastien Jamet, Elena Zamagni iD, Davide Ippolito, Michel Delforge, Francoise Kraeber-Bodéré

European Journal of Nuclear Medicine and Molecular Imaging · 2024-12 · 52 (1) · 171-192

DOI: 10.1007/s00259-024-06858-9 ↗

Kurz gefasst

Leitlinie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 29.08.2024. Verfasst von Cristina Nanni und 10 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We provide updated guidance and standards for the indication, acquisition, and interpretation of [ 18 F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [ 18 F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [ 18 F]FDG PET/CT imaging in routine practice and future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyHumansNeoplasm StagingPrognosisRadiopharmaceuticalsNuclear Medicine

Stichwörter der Autor:innen

EANM guidelinesMultiple myelomaPlasma cell disorders[18F]FDG PET/CT

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Nuclear Medicine, University Hospitals (UZ) Leuven, 3000, Leuven, Belgium.
  • Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
  • Nuclear Medicine, Comenius University, Bratislava, Slovakia.
  • Médecine Nucléaire, Hôpital Tenon, GH AP.SU, Paris, France.
  • Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.

ORCID-Profile: Elena Zamagni

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Nanni, C., Deroose, C. M., Balogova, S., Lapa, C., Withofs, N., Subesinghe, M., Jamet, B., Zamagni, E., Ippolito, D., Delforge, M., & Kraeber-Bodéré, F. (2024). EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders. European Journal of Nuclear Medicine and Molecular Imaging, 52(1), 171-192. https://doi.org/10.1007/s00259-024-06858-9

Vancouver

Nanni C, Deroose CM, Balogova S, Lapa C, Withofs N, Subesinghe M, et al. EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders. European Journal of Nuclear Medicine and Molecular Imaging. 2024;52(1):171-192. doi:10.1007/s00259-024-06858-9

BibTeX
@article{Nanni2024,
  author = {Nanni, Cristina and Deroose, Christophe M and Balogova, Sona and Lapa, Constantin and Withofs, Nadia and Subesinghe, Manil and Jamet, Bastien and Zamagni, Elena and Ippolito, Davide and Delforge, Michel and Kraeber-Bodéré, Francoise},
  title = {EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {52},
  number = {1},
  pages = {171--192},
  doi = {10.1007/s00259-024-06858-9}
}
Kostenlos starten →